Cartesian Therapeutics (RNAC) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 4660.62%.
- Cartesian Therapeutics' EBIT Margin fell 1192800.0% to 4660.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 8386.53%, marking a year-over-year decrease of 82749300.0%. This contributed to the annual value of 112.81% for FY2024, which is 2195100.0% up from last year.
- Per Cartesian Therapeutics' latest filing, its EBIT Margin stood at 4660.62% for Q3 2025, which was down 1192800.0% from 7319.13% recorded in Q2 2025.
- Cartesian Therapeutics' EBIT Margin's 5-year high stood at 3521.87% during Q4 2024, with a 5-year trough of 7319.13% in Q2 2025.
- Moreover, its 5-year median value for EBIT Margin was 64.78% (2021), whereas its average is 869.92%.
- As far as peak fluctuations go, Cartesian Therapeutics' EBIT Margin skyrocketed by 39614100bps in 2024, and later plummeted by -73602600bps in 2025.
- Quarter analysis of 5 years shows Cartesian Therapeutics' EBIT Margin stood at 13.62% in 2021, then tumbled by -471bps to 50.59% in 2022, then crashed by -769bps to 439.54% in 2023, then skyrocketed by 901bps to 3521.87% in 2024, then crashed by -232bps to 4660.62% in 2025.
- Its last three reported values are 4660.62% in Q3 2025, 7319.13% for Q2 2025, and 1989.91% during Q1 2025.